Kranthi Gorlamari v. Verrica Pharmaceuticals, Inc. et al.

Summary

The United States District Court for the Eastern District of Pennsylvania grants Plaintiff Kranthi Gorlamari’s motion for class certification in a securities-fraud action concerning alleged misstatements about FDA approval of Verrica Pharmaceuticals’ YCANTH drug. The court finds that the proposed class satisfies the requirements of Federal Rule of Civil Procedure 23, including ascertainability, numerosity, commonality, typicality, adequacy, predominance, and superiority. The court modifies the class definition by removing language excluding persons who suffered no compensable losses and the phrase “and were damaged thereby” because that language would create an impermissible fail-safe class.

Holdings

1. A class definition that includes only persons who were damaged or suffered compensable losses is impermissibly fail-safe because membership depends on whether a person ultimately has a valid claim. The court therefore removed the phrases "and were damaged thereby" and "persons and entities that suffered no compensable losses" from the class definition.
2. The proposed class was ascertainable because it was defined by objective criteria—purchases of Verrica common stock during the Class Period—and membership could be determined reliably and administratively feasibly through trading and acquisition records.
3. The proposed class satisfied numerosity, commonality, typicality, and adequacy under Rule 23(a).
4. Common questions predominated because the alleged misrepresentations, omissions, scienter, securities-law violations, and market-wide reliance issues could be addressed through generalized, classwide proof.
5. A class action was superior to other available methods of adjudication under Rule 23(b)(3).

Questions Presented

1. Whether the proposed investor class satisfied the ascertainability requirements of Rule 23.
2. Whether the proposed class definition was impermissibly fail-safe because it limited membership to persons who were damaged or suffered compensable losses.
3. Whether the proposed class satisfied Rule 23(a)'s numerosity, commonality, typicality, and adequacy requirements.
4. Whether common questions predominated under Rule 23(b)(3), including whether reliance could be presumed under Basic because Verrica stock traded in an efficient market.
5. Whether a class action was superior to other available methods of adjudication under Rule 23(b)(3).

Disposition

other